Novel Functional Imaging For Age-related Macular Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$564,848.00
Summary
Age-related macular degeneration (AMD) is an eye condition which affects the central retina (the macula) resulting in a loss of central vision. The lack of appropriate clinical tests to monitor the progression of AMD at the early stages of disease hampers the discovery of novel interventions aimed at preventing the development of advanced vision-threatening AMD. In this project, we will investigate the use of a quick and non-invasive imaging technique for monitoring AMD progression.
The Role Of Purines In Age Related Macular Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$682,434.00
Summary
Age Related Macular degeneration (AMD) is a leading cause of blindess. In this project we will examine a possible cause for the development and progression of early AMD. In particular we will determine whether signaling of immune cells via receptors called purinergic receptors influences the removal of cellular debris as we age, predisposing people to the disease.
Abnormal growth of blood vessels is a central feature of number of blinding conditions of the eye. Although there are treatments available that reduce the sudden loos of vision in a majority of people with advanced age related macular degeneration, about 20% fail to respond and half gradually loose vision. This project will determine the effectiveness of treating vascular diseases of the retina with a novel therapy that is quite different to that currently available.
Novel Photoreceptor Bioenergetics: Basic Science And Clinical Translation
Funder
National Health and Medical Research Council
Funding Amount
$701,088.00
Summary
In this project we will investigate how the light-sensitive cells in the eye (the photoreceptors) use energy and make special pigments that convert light to electrical signals. We will test novel treatments that enhance the energy supply of the photoreceptors in individuals with age-related macular degeneration.
Improving Patient Management Pathways In Age-Related Macular Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$181,065.00
Summary
Age related macular degeneration (AMD) is the most common cause of vision impairment in Australians aged over 50 years. In recent years, there have been a number of diagnostic tests and new interventions developed for AMD, but it has proven challenging to communicate this information to all primary eye care practitioners. This project will investigate the reasons management guidelines are not always being followed, and develop online training to provide direct bench-to-bedside AMD education.
The Role Of Reduced Phagocytosis In The Pathogenesis Of Age-related Macular Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$786,742.00
Summary
Understanding the underlying mechanisms which lead to age-related macular degeneration (AMD) is critical if we are to ultimately develop novel treatments. We hypothesise that there is a defective ability to remove debris that accumulates in the retina as we age and this is a crucial step in the development of AMD. We will investigate this hypothesis in an AMD cohort and in a pre-clinical model where we will test the efficacy of an intervention that improves the ability to clear debris.
A Fibroin-based Prosthetic Bruch's Membrane For The Treatment Of Age-related Macular Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$538,080.00
Summary
Our aim is to develop a new therapy for the treatment of patients with age-related macular degeneration (AMD), a leading cause of blindness in our ageing population. The novelty of our therapy resides in using a protein derived from silk fibers (fibroin), to rebuild a healthy barrier between the outermost layer of the retina and adjacent blood vessels. We expect that the findings from this study will eventually lead to better outcomes for patients with AMD.
The vision we rely on every day to read and recognise faces depends upon the health of the central portion of our retina, the macula. Age-related Macular Degeneration (AMD) is the leading cause of blindness in Australia and the western world. Researchers at the Australian National University are collaborating to bring a new test for AMD severity to the market within 3 years. The objective is to provide doctors with a rapid, cost-effective tool to help them manage treatment.
Modelling Age-related Macular Degeneration Using Patient Specific Induced Pluripotent Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$86,117.00
Summary
It is now possible to induce patient own skin cells to become stem cells. These cells can then be guided to become any cell of the body. This technique allows the study of disease cells without the need of obtaining biopsies from diseased tissue, such as the retina. This project aims to study age-related macular degeneration using patients’ stem cells, which will be differentiated into cells affected in AMD. The role of specific genetic risks in the biology of these cells will be investigated.